RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Beta-Thalassaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Screening for beta thalassemia trait in a heterogeneous university-based population in Delhi-NCR, India.
Choudhury Oishi et al., Journal of community genetics (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42894100/
- 2.
Bone Mineral Density in Adult β-Thalassaemia Major: A Cross-Sectional Z-Score-Based DXA Study from Western India
Jiya Popat et al., Indian Journal of Hematology and Blood Transfusion (16 October 2026)
https://doi.org/10.1007/s12288-026-02600-7
- 3.
Comparative Analysis of Essential Nutrients Versus Prescribed Dosages in Meeting Daily Nutritional Needs of Beta Thalassemia Major Patients
Masood Ahmad et al., International Journal of Drug Delivery Technology (15 October 2026)
https://doi.org/10.25258/ijddt.16.71s.55
- 4.
Prevalence of subclinical cardiac dysfunction and its associated risk factors in transfusion-dependent beta-thalassemia children – An experience from Central India: A cross-sectional observational study
Rajkumar Motiram Meshram et al., Heart India (9 October 2026)
https://doi.org/10.4103/heartindia.heartindia_39_26
- 5.
Distribution and Clustering of Beta-Thalassemia- and Sickle Cell-Related Disorders Among Scheduled Tribes in Tamil Nadu: An Exploratory Multivariate Analysis
Kezia Angeline J et al., Thalassemia Reports (8 October 2026)
https://doi.org/10.3390/thalassrep16040024
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)
NCT04059406 · TERMINATED · Phase 2 · Ionis Pharmaceuticals, Inc.
Ages 18 to 65
https://clinicaltrials.gov/study/NCT04059406
- 2.
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
NCT03381833 · TERMINATED · Phase 2 · La Jolla Pharmaceutical Company
Ages 14 and over
https://clinicaltrials.gov/study/NCT03381833
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Beta-Thalassaemia
Beta-thalassaemia is an inherited blood disorder caused by mutations in the HBB gene that reduce or eliminate production of the beta-globin protein, leading to anaemia of varying severity. The severe form (thalassaemia major) requires lifelong blood transfusions. Gene therapies and gene editing approaches are transforming treatment options.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Thalassemia is a major monogenic blood disorder, with India bearing a substantial burden. Although carrier screening is the most effective preventive strategy, inconsistent criteria, borderline HbA2 values, diverse mutations, and limited HbE detection hinder effectiveness. This study determines the prevalence of molecularly confirmed beta thalassemia trait (BTT) and HbE detected through a large-scale screening approach among young adults in Delhi-National Capital Region (NCR) and develops a potential scalable model for university-based carrier detection. METHODS: We recruited 4886 young adults aged 18-35 years from universities in Delhi-NCR. All blood samples underwent CBC and HPLC analysis, with selected samples subjected to genetic analysis using ARMS-PCR and Sanger sequencing. RESULTS: The prevalence of molecularly confirmed BTT and HbE trait detected through the study screening approach was 1.6% and 0.4%, respectively. Overall, 2% showed elevated HbA2 with low MCV and MCH, while 5.1% of carriers had borderline HbA2. Five common beta thalassemia mutations accounted for 84.8% of cases. Nearly 21% of samples with HbA2 4-9% showed no mutations on genetic testing. HbA2 4-9% plus low MCV and MCH showed the highest PPV, with 92% sensitivity and 88% specificity. No significant differences in BTT distribution were observed by region, religion, or social category. CONCLUSIONS: Large-scale screening for BTT among young adults in university-based settings may facilitate early carrier identification. HbA2 levels of 4-9% combined with low MCV and MCH appear to be an effective first-tier screening criterion, while further criteria are needed to identify and prioritize individuals with borderline HbA2 levels (3.2-3.9%) for molecular confirmation. Future studies should focus on developing and validating robust, context-appropriate population-level screening protocols for BTT in India.
Common Questions
What is Beta-Thalassaemia?
Beta-thalassaemia is an inherited blood disorder caused by mutations in the HBB gene that reduce or eliminate production of the beta-globin protein, leading to anaemia of varying severity. The severe form (thalassaemia major) requires lifelong blood transfusions. Gene therapies and gene editing approaches are transforming treatment options.
How many clinical trials are available for Beta-Thalassaemia?
RareWays currently indexes 70 clinical trials for Beta-Thalassaemia, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Beta-Thalassaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Beta-Thalassaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.